Adams Expands OTC Cough Market Presence With Delsym Acquisition
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics intends to aggressively promote Delsym cough suppressant to consumers following its May 24 acquisition of the brand
You may also be interested in...
FDA approves grape-flavored Delsym
FDA approved Adams Respiratory Therapeutics supplemental New Drug Application for a grape-flavored formulation for Delsym on Sept. 28 and the company will begin immediately distributing the cough medicine product, Chester, N.J.-based Adams says. Upon acquiring Delsym from USB in May 2006, the firm said it would pour $15 mil-$20 mil. annually into distribution and promotions (1"The Tan Sheet" May 29, 2006, p. 5)...
FDA approves grape-flavored Delsym
FDA approved Adams Respiratory Therapeutics supplemental New Drug Application for a grape-flavored formulation for Delsym on Sept. 28 and the company will begin immediately distributing the cough medicine product, Chester, N.J.-based Adams says. Upon acquiring Delsym from USB in May 2006, the firm said it would pour $15 mil-$20 mil. annually into distribution and promotions (1"The Tan Sheet" May 29, 2006, p. 5)...
FDA approves grape-flavored Delsym
FDA approved Adams Respiratory Therapeutics supplemental New Drug Application for a grape-flavored formulation for Delsym on Sept. 28 and the company will begin immediately distributing the cough medicine product, Chester, N.J.-based Adams says. Upon acquiring Delsym from USB in May 2006, the firm said it would pour $15 mil-$20 mil. annually into distribution and promotions (1"The Tan Sheet" May 29, 2006, p. 5)...